TY - JOUR
T1 - Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma
AU - Rocco, Alba
AU - Sgamato, Costantino
AU - Pelizzaro, Filippo
AU - Simeon, Vittorio
AU - Coccoli, Pietro
AU - Compare, Debora
AU - Pinto, Elisa
AU - Palano, Giorgio
AU - Foschi, Francesco Giuseppe
AU - Raimondo, Giovanni
AU - Missale, Gabriele
AU - Svegliati-Baroni, Gianluca
AU - Trevisani, Franco
AU - Caturelli, Eugenio
AU - Brunetto, Maurizia Rossana
AU - Vidili, Gianpaolo
AU - Masotto, Alberto
AU - Magalotti, Donatella
AU - Campani, Claudia
AU - Gasbarrini, Antonio
AU - Azzaroli, Francesco
AU - Rapaccini, Gian Ludovico
AU - Stefanini, Bernardo
AU - Sacco, Rodolfo
AU - Mega, Andrea
AU - Giannini, Edoardo Giovanni
AU - Cabibbo, Giuseppe
AU - Di Marco, Mariella
AU - Guarino, Maria
AU - Chiodini, Paolo
AU - Farinati, Fabio
AU - Nardone, Gerardo
PY - 2025
Y1 - 2025
N2 - Background/purpose of the study: We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients. Methods: Training and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models. Results: 2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11–2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11–2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD–Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort. Conclusions: NLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model’s accuracy in predicting OS.
AB - Background/purpose of the study: We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients. Methods: Training and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models. Results: 2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11–2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11–2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD–Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort. Conclusions: NLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model’s accuracy in predicting OS.
KW - Free survival
KW - Hepatocellular carcinoma
KW - Lymphocyte ratio
KW - Neutrophil
KW - Platelet
KW - Prognosis
KW - Recurrence
KW - Survival
KW - Free survival
KW - Hepatocellular carcinoma
KW - Lymphocyte ratio
KW - Neutrophil
KW - Platelet
KW - Prognosis
KW - Recurrence
KW - Survival
UR - https://publicatt.unicatt.it/handle/10807/330736
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=105001037303&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105001037303&origin=inward
U2 - 10.1007/s12072-025-10806-6
DO - 10.1007/s12072-025-10806-6
M3 - Article
SN - 1936-0533
VL - 19
SP - 915
EP - 928
JO - Hepatology International
JF - Hepatology International
IS - 4
ER -